metadata toggle
Contra-indications, warnings, etc
Do not use in animals with known hypersensitivity to gonadorelin and to any other ingredients of the product.
Do not use for shortening of oestrus during infectious diseases and other relevant disorders.
In the treatment of cystic ovaries, the condition of ovarian follicular cysts should be diagnosed by rectal palpation revealing the presence of persisting follicular structures with a diameter over 2.5 cm and should be confirmed by the use of plasma or milk progesterone assay.
The product should be administered at least 14 days after calving due to the absence of receptivity of the hypophysis before that time.
For induction and synchronisation of oestrus and ovulation in Fixed Time Artificial Insemination (FTAI) protocols, the product should be administered at least 35 days after calving. The response of cows and heifers to synchronisation protocols is influenced by the physiological state at the time of treatment. Responses to treatment can vary either across herds or across cows within herds. However, the percentage of cows displaying oestrus within a given period is usually greater than in untreated cows and the subsequent luteal phase is of normal duration.
For protocol that includes PGF: To maximise conception rates of cows to be treated, the ovarian status should be determined and regular cyclic ovarian activity confirmed. Optimal results will be achieved in healthy normally-cycling cows.
Animals in poor condition, whether from illness, inadequate nutrition or other factors, may respond poorly to treatment.
Not indicated for use during pregnancy. No contraindications have been described during lactation.
At up to 5 times the recommended dose and in a regimen extended from one to three daily administrations, no measurable signs of either local or general clinical intolerance were observed.
A synergistic effect occurs in case of combined administration of FSH.
Withdrawal period
Meat and offal: zero days.
Milk: zero hours.
User warnings
Care should be taken when handling the product to avoid self-injection. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
Care should be taken to avoid skin and eye contact. In case of skin contact, rinse immediately and thoroughly with water as GnRH analogues can be absorbed through the skin. In case of accidental contact with eyes, rinse thoroughly with plenty of water.
The effects of accidental exposure in pregnant women or in women with normal reproductive cycles are unknown; therefore it is recommended that pregnant women should not administer the product, and that women of child-bearing age should administer the product with caution.
People with known hypersensitivity to GnRH analogues, should avoid contact with the veterinary medicinal product.